Wednesday, 13 October 2021
Topics
Meeting category
Date(s)
13 Oct 2021
Program Language
English
Meeting type
Virtual Meeting
CME credits
2
Organizer
Liverpool Course 2021
Related Enduring Materials
Enduring Materials
Session 1 -
Marta Boffito, MD, PhD, FRCP, MBA
Chairs
16:00 CET
Opening: Welcome, Introduction & Goals
16:05 CET
Clinical Pharmacology of 2 Drug Regimens
16:25 CET
Clinical Pharmacology of Long-Acting Therapy: Focus on Understudied Populations
Chelsea and Westminster Hospital NHS Foundation Trust; Imperial College London; United Kingdom
17:00 CET
Quick Fire DDI Conundrums
Session 2 -
Catia Marzolini, PharmD, PhD
Chairs
University Hospital of Basel, University Hospital of Lausanne, Switzerland; University of Liverpool, United Kingdom
17:30 CET
Case 1: ARV Absorption in a Patient Undergoing Bowel Surgery
17:50 CET
Case 2: The Patient with Multiple Comorbidities. The Case for De-prescribing
18:10 CET
Case 3: The Challenge of the Patient with HIV and COVID-19
Overview
Image
Welcome
Designed and developed by renowned experts in the field of HIV care and pharmacology, the Liverpool Course aims to educate participants on key concepts in clinical pharmacology and drug-drug interactions, that remain a major consideration in the management of people living with HIV. It is organized in collaboration with the University of Liverpool and the leading experts who developed the Liverpool HIV drug interactions checker, a comprehensive drug-drug-interaction resource freely available to healthcare practitioners worldwide.
Video file
Program Chairs 2021
General Information
COVID-19 Update
Responding to the changing COVID-19 situation, the Liverpool Course 2021 will be held as a virtual conference on 13 October 2021.
The Conference Organizers will continue to observe the ongoing COVID-19 pandemic and will take necessary steps to ensure that the conference will be held in compliance with relevant regulations, prioritizing the health and safety of our participants.
We are available to answer any questions or concerns that you may have about your participation at the Liverpool Course 2021. For more information, please contact Ms. Magdalena Pawlowska at magdalena.pawlowska@amededu.com
To stay updated on developments about the Liverpool Course 2021, make sure you are signed up for our newsletter.
The Conference Organizers will continue to observe the ongoing COVID-19 pandemic and will take necessary steps to ensure that the conference will be held in compliance with relevant regulations, prioritizing the health and safety of our participants.
We are available to answer any questions or concerns that you may have about your participation at the Liverpool Course 2021. For more information, please contact Ms. Magdalena Pawlowska at magdalena.pawlowska@amededu.com
To stay updated on developments about the Liverpool Course 2021, make sure you are signed up for our newsletter.
Who should attend?
- Primary: Healthcare professionals involved in the management and treatment of people living with HIV. Priority will be given to HIV clinicians, but we will also seek to include hepatologists, pharmacists and specialist nurses.
- Secondary: ID physicians, pharmacists, specialist nurses
- Tertiary: Researchers
- Secondary: ID physicians, pharmacists, specialist nurses
- Tertiary: Researchers
Meeting Objectives
This meeting aims to:
- Reinforce and develop the understanding of key clinical pharmacology concepts among junior colleagues in the fields of infectious diseases and hepatology (clinicians, pharmacists, academics, industry colleagues etc.)
- Improve clinical pharmacology education and thereby the quality of patient care.
- Educate healthcare professionals on how to use the Liverpool Drug Interaction Resources in their clinical practice.
- Increase knowledge and confidence among healthcare professionals through practical examples of the Liverpool Drug Interactions Resources and discussion of case studies tailored to the local needs.
- Reinforce and develop the understanding of key clinical pharmacology concepts among junior colleagues in the fields of infectious diseases and hepatology (clinicians, pharmacists, academics, industry colleagues etc.)
- Improve clinical pharmacology education and thereby the quality of patient care.
- Educate healthcare professionals on how to use the Liverpool Drug Interaction Resources in their clinical practice.
- Increase knowledge and confidence among healthcare professionals through practical examples of the Liverpool Drug Interactions Resources and discussion of case studies tailored to the local needs.
Learning Objectives
After participating in this activity, participants will be able to:
- Describe in detail the terms pharmacodynamics and pharmacokinetics.
- Define what is meant by clinically significant DDI and discuss DDI mechanisms.
- Use the Liverpool DDI Resource with confidence in their daily practice.
- Identify the potential of DDIs of ARVs and DAAs and use this information to improve their decision making in daily practice.
- Describe in detail the terms pharmacodynamics and pharmacokinetics.
- Define what is meant by clinically significant DDI and discuss DDI mechanisms.
- Use the Liverpool DDI Resource with confidence in their daily practice.
- Identify the potential of DDIs of ARVs and DAAs and use this information to improve their decision making in daily practice.
Practical Information
Certificate of Attendance
A certificate of attendance will be sent to you after successfully completing the program and post-meeting survey.
Language
The official language of the meeting is English.
Disclaimer
This meeting is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organizing Secretariat of this meeting, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this meeting. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the meeting.
Liability and Insurance
By registering for the meeting participants agree that the organizers do not accept responsibility for medical-, travel- or personal insurance. Participants are advised to take out their own insurance policies.
Accreditation
Accreditation Statement
The Liverpool Course 2021, Utrecht (Livestream), Netherlands, 13/10/2021-13/10/2021 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 2 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.
Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.
Support
ViiV Healthcare
The Liverpool Course is supported by an independent educational grant from ViiV Healthcare.
ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.
Endorsers
Language
Related Programs
